Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Venus Medtech (Hangzhou), Inc. Class H ( (HK:2500) ) just unveiled an update.
Venus Medtech (Hangzhou) Inc. has scheduled a board meeting for March 31, 2026 to review and approve the audited annual results for the year ended December 31, 2025, and to authorize their publication. The meeting may also address other corporate matters, signaling the forthcoming disclosure of the company’s financial performance to investors and the market, which will provide updated insight into its operating status and governance activities.
The announcement also confirms the current composition of the board, listing its executive, non-executive and independent non-executive directors. This reinforces transparency around the company’s leadership and oversight framework at a time when investors may closely scrutinize governance and decision-making ahead of the annual results release.
The most recent analyst rating on (HK:2500) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Venus Medtech (Hangzhou), Inc. Class H stock, see the HK:2500 Stock Forecast page.
More about Venus Medtech (Hangzhou), Inc. Class H
Venus Medtech (Hangzhou) Inc. is a PRC-incorporated medical technology company listed in Hong Kong under stock code 2500. The company operates through a board comprising executive, non-executive and independent non-executive directors, reflecting a standard listed-company governance structure within the healthcare and medtech sector.
Average Trading Volume: 1,813,646
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$970.2M
For a thorough assessment of 2500 stock, go to TipRanks’ Stock Analysis page.